Business
Syngene International announces plans to add bioconjugation suite for end-to-end Antibody-Drug Conjugates Development
Syngene International, a global contract research, development and manufacturing organization (CRDMO), is adding a GMP bioconjugation suite at its commercial biologics facility [Unit 3] in Bengaluru. With this new capability, Syngene will offer fully integrated, end-to-end services for antibody-drug conjugates (ADCs) – from discovery through to GMP manufacturing – placing it among a handful of CDMOs with full-service capabilities.
About this update from Syngene International Ltd.
[{"type":"text","content":"Bioconjugation capability will complement commercial payload, linker and monoclonal antibodies services","length":103,"tagName":"p","attribs":{}},{"type":"text","content":"BENGALURU, India, Oct. 27, 2025 /PRNewswire/ -- Syngene International, a global contract research, development and manufacturing organization (CRDMO), is adding a GMP bioconjugation suite at its commercial biologics facility [Unit 3] in Bengaluru. With this new capability, Syngene will offer fully integrated, end-to-end services for antibody-drug conjugates (ADCs) – from discovery through to GMP manufacturing – placing it among a handful of CDMOs with full-service capabilities.","length":482,"tagName":"p"},{"type":"image","alt":"Syngene (PRNewsfoto/Syngene)","displaySize":"","headline":null,"caption":"Syngene (PRNewsfoto/Syngene)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":98,"url":"https://media.zenfs.com/en/prnewswire.com/e92d531eba39ab5ff9c86fab41480923"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/r8QSA0n9uAoI_k7yg7gyhg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE3MztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/e92d531eba39ab5ff9c86fab41480923","width":400,"height":98}},"href":"https://mma.prnewswire.com/media/2637918/Syngene_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The OEB-5 rated suite will accelerate ADC development timelines by enabling both Monoclonal Antibodies (mAb) production and GMP bioconjugation at a single site, complementing Syngene's existing commercial capabilities in payload and linker manufacturing. Expected to be operational within this financial year, the conjugation facility will also support a range of advanced conjugates and related modalities. These services are further strengthened by collocated analytical and bioanalytical capabilities, ensuring seamless integration across the development lifecycle.","length":572,"tagName":"p"},{"type":"text","content":""The discovery and development of ADCs is complex, often involving multiple vendors and geographically dispersed sites, which adds substantial supply chain complexity and potential delays," said Alex Del Priore, Head - LM CDMO, Syngene International."By integrating bioconjugation capabilities with our commercial-scale biologics, payload, and linker production units in Bengaluru, we ...